Petra Capital has released a research report valuing\u00a0#Orthocell (ASX:OCC) at A$1.28 per share.<\/p>\n
The report summarises Orthocell\u2019s revenue growth, and the strong outlook for the Company as it expands its global footprint with regulatory applications either planned or in progress for Remplir and Striate+.<\/p>\n
The author noted:<\/p>\n
\u201cFY24 saw OCC\u2019s Remplir and Striate products continue to gain traction after ~18 months on market. OCC is now focused on expanding the global footprint of both products. It is targeting 7 new markets, while continuing to execute on growing revenues from existing markets and progressing partnering process for Remplir and non-core tendon cell therapy (with the appointment of US advisors). A renewed Board and strong cash position are supporting this effort. We reiterate BUY, with our $1.28\/sh TP offering >3x upside.\u201d <\/em><\/p>\n